Drug Trial Radar · NCT04998812
A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Apr 13, 2022
Primary completion
Apr 8, 2024
Study completion Jul 14, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- PPD Development, LP; Laboratory Corporation of America; Illingworth Research Group
- First posted
- Aug 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the potential placental transfer of ocrelizumab in pregnant women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) \[in line with the locally approved indications\] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.
Conditions
- Multiple Sclerosis
- Clinically Isolated Syndrome
Interventions
OcrelizumabDrug
Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN)Time frame: At Week 6 of infant's life
Locations
11 sites in 5 countries. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
University Of Colorado
Aurora, Colorado
The Ken and Ruth Davee department of Neurology
Chicago, Illinois
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Hopital Pierre Wertheimer - Hopital Neurologique
Bron, France
Hôpital de la Pitié Salpétrière
Paris, France
St. Josef Hospital GmbH
Bochum, Germany
MultipEL Studies - Institut für klinische Studien
Hamburg, Germany
Hosp. Clinico San Carlos
Madrid, Spain
Universitätsspital Basel
Basel, Switzerland
Inselspital Bern
Bern, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.